Clinical Trial Update: HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of tislelizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis (PVTT).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Li Xiao Wei | Conditions: Hepatocellular Carcinoma With PVTT | Phase 2 | Status: UNKNOWN